Loading company…
Riskpilot
← Back to search
Sign in
Get full access
AB BBB Pharma
AB
Active
Org 5592144645
Skräddargårdshöjd 25
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2019
0 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -12K
0 employees
EBITDA — year on year
SEK millions
0M
4M
9M
13M
18M
0M
2020
0M
0%
2021
14M
+1400%
2022
0M
-100%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 0
—
EBITDA
—
—
Net profit
SEK -12K
—
Total assets
SEK 105K
—
Equity
SEK 105K
—
Employees
0
—
Company information
Legal name
AB BBB Pharma
Org number
5592144645
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 augusti 2019
Share capital
SEK 117 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva forskning, utveckling, assistans, undervisning och information inom medicin och därmed förenlig verksamhet.
Contact
Address
Skräddargårdshöjd 25
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Bollebygd
All Sweden companies
Revenue
SEK millions
0M
7M
15M
22M
30M
0M
2020
0M
2021
26M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
4M
8M
12M
16M
0M
2020
0M
2021
14M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
—
0
26 278
—
0
Staff expenses
—
—
—
—
—
EBITDA
0
—
14 000
0
—
Depreciation & amort.
—
−0
−0
—
−0
EBIT
0
0
14 000
0
0
Net financials
—
3
—
—
−4
Profit before tax
0
4
14 000
0
−1
Tax
—
−0
−0
—
−11
Net profit
—
4
14 000
—
−12
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
—
53
61 858
—
105
Equity
—
53
61 858
—
105
Long-term debt
—
0
0
—
0
Short-term debt
—
0
0
—
0
Total debt
—
—
—
—
—
Financial ratios
5-year trend
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
2020
2024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2020
2024
Return on equity
-11.4%
This company
18.4%
Market median
-162% vs market
2020
2024
Net profit margin
-1200000.0%
This company
8.1%
Market median
-14814915% vs market
2020
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2020
2024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2019-08-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
BE
Bo Erik Ulfson Söderpalm
Board of Directors
2022
—
—
AS
Ann-Charlott Söderpalm
Deputy Board Member
2022
—
—
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of AB BBB Pharma also hold positions in
0
other companies.
Person
Role here
Other companies
Bo Erik Ulfson Söderpalm
Board of Directors
0 companies
Ann-Charlott Söderpalm
Deputy Board Member
0 companies